CHD7 — Chromodomain Helicase DNA Binding Protein 7

CHD7 — Chromodomain Helicase DNA Binding Protein 7

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">chd7</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CHD7</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Chromodomain Helicase DNA Binding Protein 7</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>8q12.2</td>
</tr>
<tr>
<td class="label">Gene ID</td>
<td>55636</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000171316</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y5J1</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>608992</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">SOX10</td>
<td>Neural crest specification</td>
</tr>
<tr>
<td class="label">PAX3</td>
<td>Neural crest development</td>
</tr>
<tr>
<td class="label">TFAP2A</td>
<td>Craniofacial development</td>
</tr>
<tr>
<td class="label">EBF2</td>
<td>Neuronal differentiation</td>
</tr>
<tr>
<td class="label">TH</td>
<td>Dopamine synthesis</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">8 edges</a></td>
</tr>
</table>

Overview

CHD7 — Chromodomain Helicase DNA Binding Protein 7

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">chd7</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CHD7</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Chromodomain Helicase DNA Binding Protein 7</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>8q12.2</td>
</tr>
<tr>
<td class="label">Gene ID</td>
<td>55636</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000171316</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y5J1</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>608992</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">SOX10</td>
<td>Neural crest specification</td>
</tr>
<tr>
<td class="label">PAX3</td>
<td>Neural crest development</td>
</tr>
<tr>
<td class="label">TFAP2A</td>
<td>Craniofacial development</td>
</tr>
<tr>
<td class="label">EBF2</td>
<td>Neuronal differentiation</td>
</tr>
<tr>
<td class="label">TH</td>
<td>Dopamine synthesis</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">8 edges</a></td>
</tr>
</table>

Overview

CHD7 (Chromodomain Helicase DNA Binding Protein 7) encodes a large ATP-dependent chromatin remodeling factor essential for embryonic development, particularly of the neural crest, inner ear, and reproductive system. CHD7 regulates gene expression by modifying chromatin structure and facilitating enhancer-promoter interactions. Heterozygous CHD7 mutations cause CHARGE syndrome (Coloboma, Heart defects, Atresia choanae, Growth retardation, Ear abnormalities), while rarer loss-of-function variants are associated with autism spectrum disorder, intellectual disability, and potentially neurodegenerative diseases[@vissers2004][@bajpai2010].

Gene Overview

Protein Structure

Domain Architecture

CHD7 is a member of the chromodomain helicase DNA-binding (CHD) family, characterized by:

• Two chromodomains: N-terminal methyl-lysine binding domains that recognize histone modifications
• SANT domains: DNA-binding and chromatin remodeling activity
• Snf2-like ATPase domain: Helicase core that provides chromatin remodeling function
• C-terminal domain: Regulatory sequences

Chromatin Remodeling Mechanism

CHD7 uses ATP-dependent chromatin remodeling to:

Post-Translational Modifications

CHD7 activity is regulated by:

• Phosphorylation: Kinase modifications affect complex formation
• Acetylation: Histone acetyltransferase recruitment
• Sumoylation: Modulates protein interactions
• Ubiquitination: Degradation signals

Expression Pattern

Developmental Expression

During embryonic development, CHD7 is highly expressed in:

• Neural crest cells: Migratory progenitor cells giving rise to diverse cell types
• Sensory placodes: Otic (ear), optic (eye), and nasal placodes
• Developing brain: Especially proliferative zones
• Cardiovascular precursors: Heart and great vessel development

Adult Brain Expression

In the adult brain, CHD7 persists in:

• Hippocampus: Dentate gyrus and CA regions - neurogenic niches[@meijer2019]
• Cerebellum: Purkinje cells and granule cell precursors[@kim2019]
• Olfactory bulb: Continuous neurogenesis zone
• Subventricular zone: Neural stem cell niches
• Cortex: Specific layer neurons

Cell Type Specificity

CHD7 expression is enriched in:

• Neural progenitor cells
• Post-mitotic neurons
• Some glial populations (especially in development)

Function

Neural Crest Development

CHD7 is critical for neural crest specification and migration:

• Regulates transcription of key neural crest markers (SOX10, PAX3, TFAP22A)
• Controls epithelial-mesenchymal transition
• Governs migration pathways
• Influences differentiation into multiple lineages[@bajpai2010]

Neurogenesis

CHD7 plays essential roles in:

• Proliferation: Maintains neural progenitor pools
• Differentiation: Directs neuronal fate specification
• Migration: Guides neuronal positioning
• Survival: Promotes neuron survival during development[@isenberg2015]

Dopaminergic Neuron Development

Recent research shows CHD7 is important for:

• Specification of dopaminergic neurons in midbrain
• Maintenance of dopaminergic neuron populations
• Regulation of genes critical for dopamine synthesis and signaling[@zhou2018]

Cerebellar Development

CHD7 contributes to:

• Granule cell precursor proliferation
• Purkinje cell maturation
• Cerebellar circuit formation
• Motor learning circuits[@kim2019]

Disease Associations

CHARGE Syndrome

CHARGE Syndrome is caused by heterozygous CHD7 mutations and includes:

Core Features

• Coloboma: Eye abnormalities from failed optic fissure closure (70-80% of cases)
• Heart defects: Various congenital cardiac malformations (50-60%)
• Choanal atresia: Nasal passage blockage (40-50%)
• Growth retardation: Pre- and post-natal growth deficits
• Ear abnormalities: Characteristic ear shape and hearing loss (90%+)

Additional Features

• Craniofacial anomalies: Distinctive facial features
• Olfactory deficits: Anosmia or hyposmia (sensory)
• Genitourinary anomalies: In males
• Immunodeficiency: Variable T-cell deficits

Genetic Mechanism

• Most cases are de novo mutations
• Variable expressivity within families
• Genotype-phenotype correlation limited

Autism Spectrum Disorder

CHD7 variants contribute to ASD through:

• Altered social behavior gene regulation
• Impaired neural circuit development
• Synaptic function changes
• Communication and repetitive behaviors[@yu2018]

Intellectual Disability

CHD7 haploinsufficiency causes:

• Developmental delay (especially language)
• Variable cognitive impairment
• Learning disabilities
• Motor coordination deficits[@whittaker2017]

Kabuki Syndrome

Overlapping features include:

• Distinctive facial features
• Skeletal anomalies
• Developmental delays
• Immunodeficiency

Neurodegenerative Disease

Emerging evidence links CHD7 to:

Alzheimer's Disease

• Dysregulated CHD7 expression in AD brains
• May affect amyloid processing pathways
• Altered neurogenesis in AD models[@liu2020]

Parkinson's Disease

• CHD7 in dopaminergic neuron development
• Potential role in PD susceptibility
• May affect alpha-synuclein regulation

Future Directions

• More research needed on CHD7 in neurodegeneration
• Epigenetic therapies may have relevance
• Stem cell models could clarify role

Molecular Mechanisms

Transcriptional Regulation

CHD7 regulates gene expression through:

Target Genes

Key targets include:

Interaction Partners

CHD7 interacts with:

• PBAF complex: SWISNF-related chromatin remodeler
• MeCP2: Rett syndrome protein
• BRG1: ATPase subunit
• Histone acetyltransferases: p300, CBP
• Transcription factors: SOX, PAX, REST

Animal Models

Chd7 Knockout Mice

Mouse models demonstrate:

• Neural crest defects: Similar to CHARGE phenotype
• Inner ear abnormalities: Hearing loss
• Growth retardation: Reduced size
• Behavioral changes: Social interaction deficits

Heterozygous Models

• Milder phenotypes than null
• Relevant to human haploinsufficiency
• Show cognitive and social deficits

Rescue Studies

• Early intervention more effective
• Gene therapy approaches in development
• Epigenetic modulation approaches

Therapeutic Approaches

Current Strategies

• Hearing aids and cochlear implants
• Surgical interventions for structural defects
• Developmental therapies (speech, OT, PT)

Emerging Approaches

Epigenetic Therapies

• BET inhibitors: Modulate CHD7 target gene expression
• HDAC inhibitors: Histone modification agents
• Small molecule activators: Compound screening ongoing

Gene Therapy

• Viral vector delivery of wild-type CHD7
• CRISPR-based approaches
• Targeted expression systems

Future Directions

• Early intervention protocols
• Personalized medicine approaches
• Gene-specific therapies

Clinical Relevance

Genetic Testing

CHD7 testing is indicated for:

• CHARGE syndrome suspected
• Autism with additional features
• Developmental delay with hearing loss
• Multiple congenital anomalies

Prognosis

• Variable based on phenotype severity
• Early intervention improves outcomes
• Life expectancy generally normal
• Quality of life depends on interventions

Management

• Multi-disciplinary care team
• Regular monitoring of hearing, vision
• Developmental services
• Cardiac follow-up if indicated

Population Genetics

Variant Spectrum

• Missense: ~30% of pathogenic variants
• Nonsense/frameshift: ~50% of pathogenic variants
• Splice site: ~15% of pathogenic variants
• Rare deletions/duplications

Founder Effects

• Identified in some populations
• Recurrence risk assessment important

Research Directions

Current Areas of Investigation

• CHD7 in adult neurogenesis
• Epigenetic therapies for neurodevelopment
• CHD7 and psychiatric disease
• Stem cell models

Unanswered Questions

• Full spectrum of CHD7 function in brain
• Mechanisms of variable penetrance
• Long-term outcomes in adults
• Neurodegeneration link

Comparative Genomics

Evolutionary Conservation

• CHD7 is highly conserved across vertebrates
• Drosophila ortholog: kismet (KIS)
• Essential for viability in model organisms
• Conserved domains across species

Gene Family

• CHD1-9 in humans
• Subfamilies with specialized functions
• Duplication events in evolution

Epigenetics and Disease

DNA Methylation

• CHD7 function affected by DNA methylation
• Epigenetic drugs may modulate activity
• Potential therapeutic target

Histone Modifications

• CHD7 reads and writes histone marks
• Crosstalk with other epigenetic regulators
• Balance of activating/repressive marks

3D Chromatin Architecture

• CHD7 forms chromatin loops
• Enhancer-promoter contact formation
• Topologically associated domains (TADs)
• Disruption in disease states

Biomarkers and Diagnostics

Molecular Biomarkers

• CHD7 expression levels as disease indicator
• Epigenetic signatures in patient cells
• Alternative splicing patterns
• Non-coding RNA regulators

Clinical Testing

• Whole exome sequencing standard of care
• Targeted CHD7 panels available
• Copy number analysis
• Genotype-phenotype correlation tools

Model Systems

In Vitro Models

• Patient-derived iPSCs
• Neural progenitor cells
• Organoid systems
• 3D brain models

In Vivo Models

• Mouse models (knockout and conditional)
• Zebrafish models
• Xenopus models
• Drosophila models

Drug Development

Target Validation

• CHD7 as epigenetic drug target
• Modulating chromatin remodeling activity
• Indirect targeting strategies

Small Molecule Screens

• Compounds enhancing CHD7 function
• Inhibitors for specific applications
• Repurposing existing drugs

Clinical Trials

• No CHD7-specific trials yet
• Charcoal syndrome clinical centers
• Epigenetic therapy trials ongoing
• Gene therapy trials emerging

See Also

• [CHARGE Syndrome](/diseases/charge-syndrome)
• [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder)
• [Neural Crest Development](/mechanisms/neural-crest-development)
• [Chromatin Remodeling in Neurodegeneration](/mechanisms/chromatin-remodeling)

External Links

• [NCBI Gene: CHD7](https://www.ncbi.nlm.nih.gov/gene/55636)
• [UniProt: Q9Y5J1](https://www.uniprot.org/uniprot/Q9Y5J1)
• [Ensembl: ENSG00000171316](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171316)
• [OMIM: 608992](https://www.omim.org/608992)
• [GeneCards: CHD7](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CHD7)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving chd7 discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving CHD7 — Chromodomain Helicase DNA Binding Protein 7 discovered through SciDEX knowledge graph analysis: